Bringing life-saving medicines to patients — weeks faster.
We built Monipa — watches over drug production in real time, so problems are caught instantly and medicines reach patients faster.
Backed by Bioprocess360, HTGF, Verve Ventures.
Trusted by leading biopharma partners.
Now we are scaling — and inviting you in.
Trusted by leading biopharma partners.
Now we are scaling — and inviting you in.
€6+
millions raised
10+
biopharma customers
3+
active regional markets
Hear From Us
One mistake in modern drug production costs millions.
When something goes wrong during drug production, it is often discovered too late. The batch is lost. Weeks of work, gone. Expensive materials, wasted. And behind every lost batch is a patient still waiting.
Monipa catches before it becomes a problem.
Monipa monitors what is happening inside the manufacturing process — continuously, in real time, without disrupting anything. Problems are caught early. Batches are saved. And patients get their medicine on time.
Partners
We’ve had great integration of PAT tools on our production line of which IRUBIS Monipa (Mid-IR system) is one of them. IRUBIS Mid-IR is sensitive to CQA’s and byproducts in our IVT reaction, therefore enabling chemometric modelling to predict concentration for those components as well as reaction trend such as endpoint.
It was a great experience to visualize and resolve concentration profiles during our pART pDNA purification platform. We are always excited to pARTner up with innovative science and technology.
Increase product knowledge and process robustness through data connectivity and integrity – this is IRUBIS vision. We are proud to support IRUBIS excellent team with implementation of Monipa’s OPC UA interface to the PAT platform, SIMATIC SIPAT, in LivingLab Vienna.
We developed a solution for inline quality monitoring in the downstream process using a MIR Spectroscopy device, Monipa, from IRUBIS. The past 10 years have shown spectroscopic techniques to be powerful analytical tools for process development and biologics manufacturing.
CPI recognises that the biopharma industry requires the development of novel process analytical technologies (PAT) that can be deployed in and on-line to determine a variety of critical quality attributes and critical process parameters. The Monipa, developed by IRUBIS GmbH, is an example of novel PAT that can be deployed in both upstream and downstream biological applications.
Finally, a great-performing cryogen-free mid-IR device on the market which is boosting inline analysis with excellent stability and a convincing easy of handling. Definitely paving the path to more knowledge-driven process understanding, monitoring and control when combined with our PEAXACT solutions for quantitative analysis!
Investors
Your Investment, Our Milestones
First commercial footprint established in the US — the largest and fastest-growing market
Next-generation Monipa launched — expanded to serve a broader range of biopharmaceutical applications
Final certifications completed — unlocking access to the world's largest customers
The medicines of tomorrow are being built today. Be the reason they arrive faster.
Frequently Asked Questions
1What is Companisto?
Companisto is a leading DACH investment platform and Business Angel network that connects startups and growth companies with private investors. Since 2012, it has enabled over €343 million across 177+ financing rounds, combining digital investment management with access to capital, expertise, and investor networks.
2How to invest?
1. Register free on Companisto and create your investor profile.
2. Choose your amount (from €250)
3. Sign your investment documents digitally and finish.
2. Choose your amount (from €250)
3. Sign your investment documents digitally and finish.
3What return can I expect?
Your potential return depends on the future performance of IRUBIS. As a crowdinvestor, you participate in the company’s growth and may benefit from future value creation, including a potential exit or profit distributions. As with any investment, returns are not guaranteed and the invested capital is at risk. Please review the full investor information on Companisto carefully before making an investment decision.